Erste Asset Management Gmb H Bei Gene, Ltd. Transaction History

Erste Asset Management Gmb H

$8.35 Trillion
Q3 2024

A detailed history of Erste Asset Management Gmb H transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Erste Asset Management Gmb H holds 20,500 shares of BGNE stock, worth $3.7 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares

20,500

Holding current value

$3.7 Million

% of portfolio

0.05%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$143.93 - $224.51 $2.95 Million - $4.6 Million	20,500 New	20,500 $4.48 Billion
Q3 2023 Nov 26, 2024	BUY	$179.87 - $225.13 $287,792 - $360,208	1,600 Added 14.55%	12,600 $2.32 Billion
Q1 2023 Nov 26, 2024	BUY	$215.53 - $274.5 $344,848 - $439,200	1,600 Added 14.55%	12,600 $2.75 Billion
Q3 2022 Nov 26, 2024	SELL	$131.8 - $202.24 $1.25 Million - $1.92 Million	-9,500 Reduced 46.34%	11,000 $1.5 Billion
Q2 2022 Nov 26, 2024	SELL	$121.11 - $216.05 $2.01 Million - $3.59 Million	-16,600 Reduced 60.14%	11,000 $1.79 Billion
Q1 2022 Nov 22, 2024	SELL	$146.52 - $269.56 $219,780 - $404,340	-1,500 Reduced 12.0%	11,000 $2.27 Billion
Q4 2021 Nov 22, 2024	SELL	$248.56 - $389.34 $1.99 Million - $3.11 Million	-8,000 Reduced 39.02%	12,500 $3.26 Billion
Q4 2020 Nov 22, 2024	SELL	$221.31 - $316.61 $110,655 - $158,305	-500 Reduced 3.85%	12,500 $3.06 Billion
Q3 2020 Nov 22, 2024	SELL	$189.18 - $286.44 $1.42 Million - $2.15 Million	-7,500 Reduced 36.59%	13,000 $3.66 Billion
Q4 2019 Nov 22, 2024	BUY	$115.78 - $208.34 $822,038 - $1.48 Million	7,100 Added 34.63%	27,600 $4.61 Billion
Q1 2019 Nov 22, 2024	BUY	$122.82 - $151.83 $872,022 - $1.08 Million	7,100 Added 34.63%	27,600 $3.49 Billion
Q4 2018 Nov 26, 2024	BUY	$107.01 - $175.15 $759,771 - $1.24 Million	7,100 Added 34.63%	27,600 $3.8 Billion

Others Institutions Holding BGNE

# of Institutions

252

Shares Held

45.3M

Call Options Held

292K

Put Options Held

119K

View Full List

About BeiGene, Ltd.

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $18.7B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

More about BGNE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Erste Asset Management Gmb H, based on Form 13F filings with the SEC.

News

Stay updated on Erste Asset Management Gmb H with notifications on news.

Account

Erste Asset Management Gmb H Bei Gene, Ltd. Transaction History